- Home
- AGIO vs NUV Comparison
AGIO vs NUV Comparison
Compare AGIO & NUV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- NUV
- Stock Information
- Founded
- AGIO 2007
- NUV 1987
- Country
- AGIO United States
- NUV United States
- Employees
- AGIO N/A
- NUV N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- NUV Trusts Except Educational Religious and Charitable
- Sector
- AGIO Health Care
- NUV Finance
- Exchange
- AGIO Nasdaq
- NUV Nasdaq
- Market Cap
- AGIO 2.1B
- NUV 1.9B
- IPO Year
- AGIO 2013
- NUV N/A
- Fundamental
- Price
- AGIO $36.39
- NUV $8.94
- Analyst Decision
- AGIO Buy
- NUV
- Analyst Count
- AGIO 6
- NUV 0
- Target Price
- AGIO $57.00
- NUV N/A
- AVG Volume (30 Days)
- AGIO 771.2K
- NUV 464.9K
- Earning Date
- AGIO 10-30-2025
- NUV 01-01-0001
- Dividend Yield
- AGIO N/A
- NUV 3.96%
- EPS Growth
- AGIO N/A
- NUV N/A
- EPS
- AGIO 11.13
- NUV N/A
- Revenue
- AGIO $40,875,000.00
- NUV N/A
- Revenue This Year
- AGIO $28.19
- NUV N/A
- Revenue Next Year
- AGIO $152.14
- NUV N/A
- P/E Ratio
- AGIO $3.27
- NUV N/A
- Revenue Growth
- AGIO 30.57
- NUV N/A
- 52 Week Low
- AGIO $23.42
- NUV $7.86
- 52 Week High
- AGIO $62.58
- NUV $9.08
- Technical
- Relative Strength Index (RSI)
- AGIO 51.16
- NUV 80.30
- Support Level
- AGIO N/A
- NUV $8.89
- Resistance Level
- AGIO $37.18
- NUV $8.95
- Average True Range (ATR)
- AGIO 1.43
- NUV 0.04
- MACD
- AGIO -1.50
- NUV 0.02
- Stochastic Oscillator
- AGIO 88.53
- NUV 95.81
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About NUV Nuveen Municipal Value Fund Inc.
Nuveen Municipal Value Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations issued by state and local government authorities or certain U.S. territories.